

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>A61K 31/135, 47/18</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 00/21521</b> <b>(43) International Publication Date:</b> 20 April 2000 (20.04.00)
<b>(21) International Application Number:</b> PCT/IB99/01571 <b>(22) International Filing Date:</b> 22 September 1999 (22.09.99) <b>(30) Priority Data:</b> 60/104,024 13 October 1998 (13.10.98) US <b>(71) Applicant (for all designated States except US):</b> PFIZER PRODUCTS INC. [US/US]; Eastern Point Road, Groton, CT 06340 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> HARPER, Nancy, Jane [US/US]; 164 Shore Avenue, Groton, CT 06340 (US). RANADE, Gautam, Ramchandra [IN/US]; 18 Wayne Drive, East Lyme, CT 06333 (US). WELCH, Willard, McKowan [US/US]; 116 Pequot Avenue, Mystic, CT 06355 (US). <b>(74) Agents:</b> SPIEGEL, Allen, J. et al.; Pfizer Inc., Patent Dept., 235 East 42nd Street, New York, NY 10017 (US).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> SERTRALINE ORAL CONCENTRATE		
<b>(57) Abstract</b> <p>The present invention provides an essentially nonaqueous, liquid pharmaceutical concentrate composition for oral administration containing sertraline or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The present invention also provides a use of this concentrate composition to prepare an aqueous solution of sertraline. In addition, the present invention provides a method of using this concentrate composition to treat or prevent a variety of diseases or conditions. Finally, the present invention provides the compound, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine methanesulfonate.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

-1-


## SERTRALINE ORAL CONCENTRATE

## FIELD OF THE INVENTION

The present invention provides an essentially nonaqueous, liquid  
5 pharmaceutical concentrate composition for oral administration containing sertraline  
or a pharmaceutically acceptable salt thereof and one or more pharmaceutically  
acceptable excipients. The present invention also provides a use of this concentrate  
composition to prepare an aqueous solution of sertraline. In addition, the present  
invention provides a method of using this concentrate composition to treat or prevent  
10 a variety of diseases or conditions. Finally, the present invention provides the  
compound, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-  
naphthalenamine methanesulfonate.

## BACKGROUND OF THE INVENTION

15 Sertraline is a known compound having the following structure:



Sertraline has the following chemical name: (1S-cis)-4-(3,4-dichlorophenyl)-  
20 1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine. Sertraline and its pharmaceutically  
acceptable acid addition salts, such as the hydrochloride salt, are disclosed in U.S.  
Patent No. 4,536,518, which issued on 20 August 1985, (hereafter referred to as the  
'518 patent), which is herein incorporated by reference in its entirety. Another  
pharmaceutically acceptable salt of sertraline is the mesylate salt.

25 The '518 patent states that sertraline and derivatives thereof are useful as  
antidepressant agents. U.S. Patent No. 5,130,338, which issued on 14 July 1992,

refers to the use of sertraline to treat chemical dependencies, including dependencies on alcohol, tobacco and cocaine. U.S. Patent No. 4,962,128, which issued on 9 October 1990, refers to the use of sertraline to treat anxiety related disorders such as panic disorder, obsessive-compulsive disorder, generalized anxiety disorder, phobias, 5 post traumatic stress disorder and avoidant personality disorder. U.S. Patent No. 4,940,731, which issued on 10 July 1990, refers to the use of sertraline to treat premature ejaculation. Published PCT patent application, WO 96/22085, which was published on 25 July 1996, refers to the use of sertraline to treat cancer patients. Published European patent application 0768083, which published on 16 April 1997, 10 refers to the use of sertraline to treat post myocardial infarction patients.

U.S. Patent No. 5,597,826, which issued on 28 January 1997, relates to novel compositions containing a serotonin selective reuptake inhibitor (SSRI), such as sertraline, and an agonist or antagonist of the serotonin 1 (5-HT<sub>1</sub>) receptor and to the use of such compositions for treating or preventing a condition selected from mood 15 disorders, including depression, seasonal affective disorders and dysthymia, anxiety disorders, including generalized anxiety disorder and panic disorder; agoraphobia, avoidant personality disorder; social phobia; obsessive compulsive disorder; post-traumatic stress disorder; memory disorders including dementia, amnesic disorders and age-associated memory impairment; disorders of eating behavior, including 20 anorexia nervosa and bulimia nervosa; obesity; cluster headache; migraine; pain; Alzheimer's disease; chronic paroxysmal hemicrania; headache associated with vascular disorders; Parkinson's disease, including dementia in Parkinson's disease, neuroleptic-induced parkinsonism and tardive dyskinesias; endocrine disorders such as hyperprolactinaemia; vasospasm (particularly in the cerebral vasculature); 25 hypertension; disorders in the gastrointestinal tract where changes in motility and secretion are involved; sexual dysfunction, including premature ejaculation; and chemical dependencies. The foregoing published applications and U.S. patents are herein incorporated by reference in their entireties.

As noted above, sertraline hydrochloride is a selective serotonin reuptake 30 inhibitor (SSRI) for oral administration. (Physicians' Desk Reference (PDR), 52nd ed., Supplement A, pages A250-A255 (1998).) Its mechanism, pharmacokinetics, and metabolism confer safety, once-daily dosage and efficacy in the treatment of depression, obsessive-compulsive disorder and panic disorder. It is approved for the

treatment of one or more of these indications in over 60 countries worldwide. The daily doses for sertraline, expressed as the free base, range from 50-200 mg, increasing in 50 mg increments. A titration dose of 25 mg/day during the initial phase of therapy may be warranted in some indications.

5           Tablet and capsule formulations of sertraline hydrochloride are commercially available in different countries. Capsular-shaped, scored tablets are available in strengths of 50 and 100 mg and are sold under the brand name, ZOLOFT® Tablets, in the U.S. The capsules are available in some countries in strengths of 50 mg and 100 mg.

10           The '518 patent discloses that sertraline and related compounds can be administered in a wide variety of different dosage forms, i.e., they may be combined with various pharmaceutically-acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, sprays, aqueous suspension, injectable solutions, elixirs, syrups, and the like. According to this patent, when  
15           aqueous suspensions and/or elixirs are desired for oral administration, the essential active ingredient therein may be combined with various sweetening, or flavoring agents, coloring matter or dyes and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.

20           However, development of an oral liquid dosage form of sertraline has been complicated by the objectionable bitter taste and astringency sensation imparted by the drug in liquid form. Thus, direct ("ready-to-use") oral liquid solutions or suspensions of sertraline, such as those described in the '518 patent above, have an objectionable taste, despite the inclusion of a variety of taste-masking or flavoring  
25           agents.

          An oral liquid dosage form of sertraline with acceptable taste would be a valuable addition to the existing formulations, providing greater choice for both the prescriber and the patient. This is of importance with regard to the issue of non-compliance with treatment, which is believed to affect up to 50% of outpatients  
30           and appears to be a particular problem with elderly, pediatric and psychiatric patients (B. Blackwell, Drug Therapy: Patient Compliance, N.Engl.J.Med. 1973, 289(5):249-52). By virtue of being easier to swallow, an oral liquid dosage form of sertraline would offer an alternative to those patients who dislike or have difficulty swallowing

tablets or capsules, and would therefore be of considerable benefit in treating those who may be non-compliant for those reasons. Therefore, there is a need in the art for an alternative liquid dosage form of sertraline that has acceptable taste and properties.

- 5 Oral concentrate drug products are known in the art and are commercially available. However, these concentrates are conventionally aqueous. For example, NAVANE® Concentrate contains the active ingredient, thiothixene hydrochloride, and the inert ingredients of alcohol, cherry flavor, dextrose, passion fruit flavor, sorbitol solution and water. (Physicians' Desk Reference (PDR), 52nd ed., pages 2192-2193
- 10 (1998).) SINEQUAN® Concentrate contains the active ingredient, doxepin hydrochloride, and the inert ingredients of glycerin, methylparaben, peppermint oil, propylparaben and water. (Physicians' Desk Reference (PDR), 52nd ed., pages 2203-2204 (1998).) TRILAFON® Concentrate contains the active ingredient,
- 15 sodium phosphate, sorbitol, sugar and water. (Physicians' Desk Reference (PDR), 52nd ed., pages 2666-2668 (1998)).

#### SUMMARY OF THE INVENTION

The present invention particularly provides:

- 20 A pharmaceutical composition which comprises:  
an essentially nonaqueous, liquid concentrate for oral administration comprising an amount of sertraline or a pharmaceutically acceptable salt thereof and one or more essentially nonaqueous pharmaceutically acceptable excipients; wherein at least one of the excipients is liquid. Preferably, the pharmaceutically acceptable
- 25 salts of sertraline are the hydrochloride salt and the mesylate salt.

- More particularly, the present invention provides this composition wherein the concentrate contains sertraline hydrochloride, ethanol and glycerin. More specifically, in this concentrate, the sertraline hydrochloride is present in an amount of about 15 to about 30 mg/ml and the ethanol and glycerin are present at about 8 to about 20%
- 30 ethanol (by weight) in glycerin.

The present invention also provides this composition wherein the concentrate contains sertraline hydrochloride, ethanol, glycerin and menthol. More specifically, in

this concentrate, the sertraline hydrochloride is present in an amount of about 15 to about 30 mg/ml, the ethanol and glycerin are present at about 8 to about 20% ethanol (by weight) in glycerin, and the menthol is present in an amount of about 0.01 to about 5.0 mg/ml.

5 Most particularly, the present invention provides this composition wherein the concentrate contains sertraline hydrochloride, glycerin, ethanol, butylhydroxytoluene (BHT) and menthol. More specifically, each ml of this concentrate contains about 22.4 mg of sertraline hydrochloride, about 151 mg of ethanol, about 0.50 mg of menthol, about 0.10 mg of BHT, and a sufficient quantity of glycerin (which is about  
10 1011 mg) to produce about 1 ml.

The present invention also provides the use of this essentially nonaqueous, liquid concentrate of sertraline or a pharmaceutically acceptable salt thereof to prepare an aqueous solution of sertraline which comprises: diluting the concentrate in an aqueous diluent prior to oral administration. Preferably, the pharmaceutically  
15 acceptable salts of sertraline are the hydrochloride salt and the mesylate salt.

The present invention also provides a method of treating or preventing diseases or conditions which are caused by disorders of the serotonergic system which comprises: a) diluting this concentrate in an aqueous diluent; and b) orally administering the resulting aqueous solution to a patient in need thereof. In addition,  
20 the present invention provides this method for treating or preventing diseases or conditions, such as the following: depression, anorexia, chemical dependencies, anxiety-related disorders (such as panic disorder, obsessive-compulsive disorder, generalized anxiety disorder, phobias, post traumatic stress disorder and avoidant personality disorder), premature ejaculation, cancer and post myocardial infarction.

25 The present invention also provides a process for making this essentially nonaqueous, liquid concentrate of sertraline or a pharmaceutically acceptable salt thereof.

Finally, the present invention provides the compound, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine methanesulfonate.  
30

#### DETAILED DESCRIPTION OF THE INVENTION

"Essentially nonaqueous" when used herein refers to the amount of water that is present in the final drug product, which amount is consistent with the amount of

water potentially contributed by the active ingredient and/or by the excipients; however, no water is directly added to the final drug product. About 10% is the upper limit of the amount of water that may be present in the oral concentrate of the present invention. Typically, the amount of water that is present in the oral concentrate of the present invention ranges from about 0.8% to about 5.2% of the composition. Most typically, the amount of water that is present ranges from about 0.8% to about 2.0% of the composition.

"Concentrate" when used herein refers to a strong solution provided for dilution before use. (Butterworths Medical Dictionary, 2nd edition, Butterworths, London - Boston 1978, pp. 399-400.)

"Pharmaceutically acceptable excipient," as used herein, means a pharmacologically inactive ingredient which is used to formulate a drug product and which is readily known and available in the pharmaceutical arts. Examples of such excipients are given below.

"Pharmaceutically acceptable preservative," as used herein, means an additive or excipient that preserves the quality of the formulation from a chemical or microbiological standpoint. Examples of preservatives are given below.

"Serotonergic system" when used herein refers to the neuronal process whereby serotonin is released by a pre-synaptic cell upon excitation and crosses the synapse to stimulate or inhibit the post-synaptic cell.

The sertraline oral concentrate of the present invention is a new dosage form of sertraline intended as a multidose product for oral use only. The oral concentrate is an essentially non-aqueous, optionally flavored solution of sertraline, preferably as the hydrochloride salt, which is intended to be diluted prior to administration.

The oral concentrate of the present invention is advantageous because, *inter alia*, it provides convenience in measuring different doses, which are needed for certain indications, and acceptable taste upon administration, as well as good physical/chemical stability characteristics throughout the product's shelf-life and use interval. Also, since the concentrate of the present invention is a solution, it is preferred over a suspension for ease of manufacture and optimal control of dosing homogeneity.

The active ingredient in the concentrate of the present invention is sertraline, which may be present as its free base or as its pharmaceutically acceptable salt.



Such salts include, for example, the hydrochloride salt and the methanesulfonate salt (also known as the mesylate salt). In the concentrate of the present invention, the hydrochloride salt is preferred.

5 The preparation of sertraline and its hydrochloride salt is described in the '518 patent referenced above, particularly in Example 2 of that patent. The mesylate salt is prepared by reacting the sertraline free base with methanesulfonic acid at room temperature in a solvent, such as ethyl acetate, methanol, ethanol and isopropanol. The mesylate salt has favorable properties, such as solubility in polar vehicles and good chemical stability.

10 Sertraline hydrochloride may be present in the concentrate of the present invention in an amount of about 1 mg/ml up to about 88 mg/ml of the composition. Preferably, it is present in an amount of about 15 to about 30 mg/ml of the composition. Most preferably, about 20 mg sertraline per ml, which is equivalent to about 22.4 mg/ml as the hydrochloride (assuming a theoretical stoichiometric potency of 89.4%), is present. The quantity of sertraline hydrochloride needed to produce a  
15 concentration of about 20 mg sertraline per ml is adjusted based on the actual potency of the drug substance lot to be used.

One or more pharmaceutically acceptable excipients are present in the concentrate of the present invention. Examples of such excipients include the  
20 following: ethanol, glycerin (also referred to as glycerol or glycerine), propylene glycol and polyethylene glycols. All of these excipients are well known in the pharmaceutical arts and are commercially available.

From among these excipients, binary combinations of ethanol and glycerin provide maximum solubilization of the sertraline hydrochloride drug substance and  
25 are preferred. In these combinations, the amount of ethanol that is present is about 8% to about 50% (w/w) in glycerin; preferably, about 8 to about 20% (w/w) ethanol in glycerin is present; most preferably, about 10 to about 14% (w/w) ethanol in glycerin is present. The ethanol that may be used in the concentrate of the present invention is any compendial grade of ethanol, including ethanol (95%) and anhydrous ethanol.

30 The concentrate of the present invention optionally contains one or more flavoring agents or taste-masking flavors. Examples of candy-type flavoring agents include mint, citrus and fruit flavoring agents. The mint flavoring agents, such as peppermint, spearmint and menthol (also referred to as levomenthol), are preferred.

More specifically, from among a variety of mint flavoring agents, menthol is preferred and may be present in an amount of about 0.01 to about 5.0 mg/ml of the composition; preferably, menthol is present in an amount of about 0.5 mg/ml of the composition.

5           The concentrate of the present invention also optionally contains one or more pharmaceutically acceptable preservatives, which preserve the quality of the concentrate from a chemical or microbiological standpoint. Preservatives, such as antioxidants, metal chelators, metal complexing agents and antimicrobial agents, may be used in the concentrate of the present invention. These preservatives may be  
10       used in the concentrate, both alone and in various combinations (e.g., antioxidant(s) in combination with a metal complexing agent), to improve product stability. When the concentrate of the present invention contains ethanol, it may be appropriately microbiologically self-preserved.

          Examples of preservatives, which may be present in the concentrate of the  
15       present invention, include the following: butylhydroxytoluene (BHT, also referred to as butylated hydroxytoluene), butylated hydroxyanisole (BHA), propyl gallate, ascorbic acid, ascorbyl palmitate, sodium metabisulfite, sodium bisulfite, sodium thiosulfate, sodium hydroxide, cystiene, ethylenediamine tetraacetic acid (EDTA) or its salts (such as the sodium salt), citric acid, triethanolamine, thioglycerol,  
20       methylparaben and propylparaben. Also, various combinations of these preservatives may be present in the concentrate of the present invention, such as the following: disodium EDTA and BHA; disodium EDTA, BHA and BHT; disodium EDTA and propyl gallate; and BHA and BHT.

          The amount of preservative that may be present in the concentrate of the  
25       present invention ranges from about 0.01 to about 10.0 mg/ml of the composition. In the concentrate of the present invention, butylhydroxytoluene (BHT) is preferred and may be present in an amount of about 0.01 to about 0.5 mg/ml of the composition; preferably, it is present in an amount of about 0.01 to about 0.2 mg/ml of the composition; more preferably, it is present in amount of about 0.01 to about 0.13  
30       mg/ml of the composition; most preferably, it is present in an amount of about 0.05 to about 0.11 mg/ml of the composition.

          The sertraline oral concentrate of the present invention is intended to be diluted in a suitable diluent or beverage prior to administration. For example, doses

of the oral concentrate (equivalent to about 25 mg and about 200 mg of sertraline) are mixed with approximately 4 oz. (about 120 ml or 1/2 cup) of a suitable diluent or beverage. The following beverages may be used for the preparation and administration of the dose: water, orange juice, ginger ale, lemon-lime soda, 5 lemonade, sugared tap water, cranberry juice, grapefruit juice, tomato juice, pineapple juice, prune juice, orange drink and Gatorade® (beverage, not powder). Water, orange juice, ginger ale, lemon-lime soda and lemonade are preferred. The proper dose of sertraline oral concentrate may be most conveniently added to these beverages by means of a dropper calibrated at, for example, 25 and 50 mg (as 10 sertraline).

The manufacture of sertraline oral concentrate utilizes conventional pharmaceutical equipment and processes. For example, the manufacturing process for sertraline hydrochloride oral concentrate involves dissolving the sertraline hydrochloride drug substance in a solution of glycerin, ethanol, and optionally other 15 excipients, such as butylhydroxytoluene (BHT) and menthol, followed by clarifying filtration, if desired, and filling into containers such as bottles, as appropriate.

Preferably, to facilitate BHT incorporation, this component is first dissolved in a portion of the ethanol, which is then added to the main compounding tank containing the glycerin and the remainder of the ethanol. Menthol and sertraline 20 hydrochloride are then sequentially added and mixed to dissolve. The sertraline hydrochloride is intentionally added to the solution last to optimize the protective effect of the antioxidant (BHT). The compounded solution is passed through a filter, and the final product is filled into appropriate containers, such as bottles. The final product may be supplied in a variety of presentations, such as a 60 ml presentation, 25 which is packaged in, for example, a 60 ml, amber glass bottle with a child-resistant closure.

## EXAMPLES

## EXAMPLE 1

Concentrate solution (20 mg sertraline/ml) with preservative and menthol flavoring:

5

Ingredients	mg/ml	% w/v (g/100ml)	mg/60ml
Sertraline HCl	22.37	2.237	1342.3
Ethanol (95%)	150.68	15.068	9040.8
Menthol	0.50	0.050	30.0
BHT	0.10	0.010	6.0
Glycerin	1010.81	101.081	60648.6
Total	1184.46	118.446	71067.7

- BHT, menthol and drug were dissolved in a mixture of glycerin and ethanol. The resulting mixture may be blanketed with nitrogen due to the ethanol content and associated potential flammability. The resulting mixture may be filtered, if desired.

10

## EXAMPLE 2

One ml of a nonaqueous solution containing 1-23 mg sertraline HCl/ml:

Sertraline Hydrochloride: 1 - 23 mg

Polyethylene glycol 300 (PEG-300): sufficient quantity to produce 1 ml

15

Dissolve the drug substance in the PEG with stirring.

## EXAMPLE 3

One ml of a nonaqueous solution containing 1 - 64 mg sertraline HCl/ml:

Sertraline Hydrochloride: 1 - 64 mg

Propylene Glycol: sufficient quantity to produce 1 ml

20

Dissolve the drug substance in the propylene glycol with stirring.

## EXAMPLE 4

One ml of a nonaqueous solution containing 1 - 17 mg sertraline HCl/ml:

Sertraline Hydrochloride: 1 - 17 mg

Ethanol: sufficient quantity to produce 1 ml

25

Dissolve the drug substance in the ethanol with stirring.

## EXAMPLE 5

One ml of a nonaqueous solution containing 1 - 78 mg sertraline HCl/ml:

Sertraline Hydrochloride: 1 - 78 mg

Ethanol: 100 - 500 mg

5 Glycerin: sufficient quantity to produce 1 ml

Dissolve the drug substance in a mixture of ethanol and glycerin with stirring.

## EXAMPLE 6

1000 ml concentrate solution (20 mg sertraline/ml) with peppermint flavoring:

Sertraline HCl : 22.4 g

10 Ethanol (95%): 127 g

Natural Peppermint Stick flavoring: 0.01 - 1.7 g

Glycerin: 852 - 872 g or sufficient quantity to produce 1000 ml

Dissolve the natural peppermint stick flavoring and drug in a mixture of ethanol and glycerin.

## 15 EXAMPLE 7

1000 ml concentrate solution (20 mg sertraline/ml) with menthol flavoring:

Sertraline HCl : 22.4 g

Ethanol (95%): 127 g

Menthol: 0.01 - 1.7 g

20 Glycerin: 852 - 872 g or sufficient quantity to produce 1000 ml

Dissolve the menthol and drug in a mixture of ethanol and glycerin.

## EXAMPLE 8

1000 ml concentrate solution (20 mg sertraline/ml) with preservatives and peppermint flavoring:

25 Sertraline HCl : 22.4 g

Ethanol, anhydrous: 127 g

Natural Peppermint Stick flavoring: 1.7 g

Methylparaben: 0.6 g

Propylparaben: 0.3 g

30 Glycerin: 852 - 872 g or sufficient quantity to produce 1000 ml

The natural peppermint stick flavoring, parabens and drug were dissolved in a mixture of ethanol/glycerin.

## EXAMPLE 9

1000 ml concentrate solution (20 mg sertraline/ml) with preservatives and no flavoring:

Sertraline HCl : 22.4 g

5 Ethanol, anhydrous: 127 g

Methylparaben: 0.6 g

Propylparaben: 0.3 g

Glycerin: 852 - 872 g or sufficient quantity to produce 1000 ml

The parabens and drug were dissolved in a mixture of ethanol/glycerin.

10 EXAMPLES 10-30

The following examples describe various 1000 ml concentrate solutions of sertraline hydrochloride (20 mg sertraline/ml) with preservatives and menthol flavoring:

## EXAMPLE 10

Sertraline HCl: 22.7 g

15 Ethanol, 95%: 151.0 g

Menthol: 0.5 g

Citric acid: 0.1 g

Glycerin: 1010.7 g or sufficient quantity to produce 1000 ml

## EXAMPLE 11

20 Sertraline HCl: 22.7 g

Ethanol, 95%: 151.0 g

Menthol: 0.5 g

Propyl gallate: 0.1 g

Glycerin: 1010.7 g or sufficient quantity to produce 1000 ml

25 EXAMPLE 12

Sertraline HCl: 22.7 g

Ethanol, 95%: 151.0 g

Menthol: 0.5 g

BHA: 0.1 g

30 Glycerin: 1010.7 g or sufficient quantity to produce 1000 ml

## EXAMPLE 13

Sertraline HCl: 22.7 g

Ethanol, 95%: 151.0 g

Menthol: 0.5 g

Sodium metabisulfite: 0.5 g

Glycerin: 1010.7 g or sufficient quantity to produce 1000 ml

5 EXAMPLE 14

Sertraline HCl: 22.7 g

Ethanol, 95%: 151.0 g

Menthol: 0.5 g

Ascorbyl palmitate: 0.1 g

10 Glycerin: 1010.7 g or sufficient quantity to produce 1000 ml

EXAMPLE 15

Sertraline HCl: 22.7 g

Ethanol, 95%: 151.0 g

Menthol: 0.5 g

15 Sodium bisulfite: 0.5 g

Glycerin: 1010.7 g or sufficient quantity to produce 1000 ml

EXAMPLE 16

Sertraline HCl: 22.7 g

Ethanol, 95%: 151.0 g

20 Menthol: 0.5 g

Triethanolamine: 0.1 - 0.5 g

Glycerin: 1010.7 g or sufficient quantity to produce 1000 ml

EXAMPLE 17

Sertraline HCl: 22.7 g

25 Ethanol, 95%: 151.0 g

Menthol: 0.5 g

BHT: 0.1 g

Glycerin: 1010.7 g or sufficient quantity to produce 1000 ml

EXAMPLE 18

30 Sertraline HCl: 22.7 g

Ethanol, 95%: 151.0 g

Menthol: 0.5 g

1N sodium hydroxide: 0.03 g

Glycerin: 1010.7 g or sufficient quantity to produce 1000 ml

EXAMPLE 19

Sertraline HCl: 22.7 g

5 Ethanol, 95%: 151.0 g

Menthol: 0.5 g

Disodium EDTA: 0.1 g

Glycerin: 1010.7 g or sufficient quantity to produce 1000 ml

EXAMPLE 20

10 Sertraline HCl: 22.7 g

Ethanol, 95%: 151.0 g

Menthol: 0.5 g

Ascorbic acid: 0.1 g

Glycerin: 1010.7 g or sufficient quantity to produce 1000 ml

15 EXAMPLE 21

Sertraline HCl: 22.7 g

Ethanol, 95%: 151.0 g

Menthol: 0.5 g

Thioglycerol: 1.0 g

20 Glycerin: 1010.7 g or sufficient quantity to produce 1000 ml

EXAMPLE 22

Sertraline HCl: 22.7 g

Ethanol, 95%: 151.0 g

Menthol: 0.5 g

25 Sodium thiosulfate: 0.5 g

Glycerin: 1010.7 g or sufficient quantity to produce 1000 ml

EXAMPLE 23

Sertraline HCl: 22.7 g

Ethanol, 95%: 151.0 g

30 Menthol: 0.5 g

BHT: 0.1 g

BHA: 0.1 g



Glycerin: 1010.7 g or sufficient quantity to produce 1000 ml

EXAMPLE 24

Sertraline HCl: 22.7 g

Ethanol, 95%: 151.0 g

5 Menthol: 0.5 g

BHT: 0.1 g

BHA: 0.1 g

Citric acid: 0.1 g

Glycerin: 1010.7 g or sufficient quantity to produce 1000 ml

10 EXAMPLE 25

Sertraline HCl: 22.7 g

Ethanol, 95%: 151.0 g

Menthol: 0.5 g

BHT: 0.1 g

15 BHA: 0.1 g

Propyl gallate: 0.1 g

Glycerin: 1010.7 g or sufficient quantity to produce 1000 ml

EXAMPLE 26

Sertraline HCl: 22.7 g

20 Ethanol, 95%: 151.0 g

Menthol: 0.5 g

Disodium EDTA: 0.1 g

Sodium metabisulfite: 0.5 g

Glycerin: 1010.7 g or sufficient quantity to produce 1000 ml

25 EXAMPLE 27

Sertraline HCl: 22.7 g

Ethanol, 95%: 151.0 g

Menthol: 0.5 g

Cystiene: 1.0 g

30 Glycerin: 1010.7 g or sufficient quantity to produce 1000 ml

EXAMPLE 28

Sertraline HCl: 22.7 g

Ethanol, 95%: 151.0 g

Menthol: 0.5 g

BHT: 0.1 g

BHA: 0.1 g

5 Triethanolamine: 0.1 - 0.5 g

Glycerin: 1010.7 g or sufficient quantity to produce 1000 ml

#### EXAMPLE 29

Sertraline HCl: 22.7 g

Ethanol, 95%: 151.0 g

10 Menthol: 0.5 g

Disodium EDTA: 0.1 g

BHT: 0.1 g

BHA: 0.1 g

Glycerin: 1010.7 g or sufficient quantity to produce 1000 ml

15 EXAMPLE 30

Sertraline HCl: 22.7 g

Ethanol, 95%: 151.0 g

Menthol: 0.5 g

Disodium EDTA: 0.1 g

20 BHA: 0.1 g

Glycerin: 1010.7 g or sufficient quantity to produce 1000 ml

For Examples 10-30 above, the menthol and preservative were dissolved in ethanol.

Glycerin was added and dispersed. The drug was added and dissolved.

## CLAIMS

1. A pharmaceutical composition which comprises:  
an essentially nonaqueous, liquid concentrate for oral administration  
comprising an amount of sertraline or a pharmaceutically acceptable salt thereof and  
5 one or more essentially nonaqueous pharmaceutically acceptable excipients; wherein  
at least one of the excipients is liquid.
2. The composition of claim 1 wherein the pharmaceutically acceptable salt of  
sertraline is the hydrochloride salt or the mesylate salt.
3. The composition of claim 1 wherein the excipients are selected from the  
10 group consisting of ethanol, glycerin, polyethylene glycol and propylene glycols.
4. The composition of claim 3 wherein the excipients are ethanol and glycerin.
5. The composition of claim 1 wherein the concentrate comprises sertraline  
hydrochloride in an amount of about 15 to about 30 mg/ml and wherein the excipients  
are ethanol and glycerin in an amount of about 8 to about 20% ethanol (by weight) in  
15 glycerin.
6. The composition of claim 5 wherein the concentrate further comprises one or  
more flavoring agents and one or more pharmaceutically acceptable preservatives.
7. The composition of claim 6 wherein the flavoring agents are selected from the  
group consisting of peppermint, spearmint and menthol; and wherein the  
20 preservatives are selected from the group consisting of butylhydroxytoluene,  
butylated hydroxyanisole, propyl gallate, ascorbic acid, ascorbyl palmitate, sodium  
metabisulfite, sodium bisulfite, sodium thiosulfate, sodium hydroxide, cystiene,  
ethylenediamine tetraacetic acid or salts thereof, citric acid, triethanolamine,  
thioglycerol, methylparaben and propylparaben.
- 25 8. The composition of claim 7 wherein the flavoring agent is menthol and  
wherein the preservative is butylhydroxytoluene.
9. The composition of claim 8 wherein each ml of the concentrate comprises  
about 22.4 mg of sertraline hydrochloride, about 151 mg of ethanol, about 0.50 mg of  
menthol, about 0.10 mg of butylhydroxytoluene, and about 1011 mg of glycerin.
- 30 10. The compound, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-  
naphthalenamine methanesulfonate.
11. Use of an essentially nonaqueous, liquid concentrate of sertraline or a  
pharmaceutically acceptable salt thereof of claim 1 to prepare an aqueous solution of

sertraline which comprises diluting the concentrate in an aqueous diluent prior to oral administration.

12. The use of claim 11 wherein the pharmaceutically acceptable salt of sertraline is the hydrochloride salt or the mesylate salt.
- 5 13. The use of claim 11 wherein the diluent is selected from the group consisting of water, orange juice, ginger ale, lemon-lime soda and lemonade.



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 7 :</b> A61K 31/135, 47/10	<b>A3</b>	<b>(11) International Publication Number:</b> WO 00/21521 <b>(43) International Publication Date:</b> 20 April 2000 (20.04.00)
<b>(21) International Application Number:</b> PCT/IB99/01571 <b>(22) International Filing Date:</b> 22 September 1999 (22.09.99) <b>(30) Priority Data:</b> 60/104,024 13 October 1998 (13.10.98) US <b>(71) Applicant (for all designated States except US):</b> PFIZER PRODUCTS INC. [US/US]; Eastern Point Road, Groton, CT 06340 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> HARPER, Nancy, Jane [US/US]; 164 Shore Avenue, Groton, CT 06340 (US). RANADE, Gautam, Ramchandra [IN/US]; 18 Wayne Drive, East Lyme, CT 06333 (US). WELCH, Willard, McKowan [US/US]; 116 Pequot Avenue, Mystic, CT 06355 (US). <b>(74) Agents:</b> SPIEGEL, Allen, J. et al.; Pfizer Inc., Patent Dept., 235 East 42nd Street, New York, NY 10017 (US).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <b>(88) Date of publication of the international search report:</b> 20 July 2000 (20.07.00)
<b>(54) Title:</b> SERTRALINE ORAL CONCENTRATE		
<b>(57) Abstract</b> <p>The present invention provides an essentially nonaqueous, liquid pharmaceutical concentrate composition for oral administration containing sertraline or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The present invention also provides a use of this concentrate composition to prepare an aqueous solution of sertraline. In addition, the present invention provides a method of using this concentrate composition to treat or prevent a variety of diseases or conditions. Finally, the present invention provides the compound, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine methanesulfonate.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the P

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

# INTERNATIONAL SEARCH REPORT

Int. onal Application No

PCT/IB 99/01571

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/135 A61K47/10

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 030 081 A (PFIZER) 10 June 1981 (1981-06-10) cited in the application example 24A	10
A	CA 2 143 070 A (P. MODI) 23 August 1995 (1995-08-23) claims	1-13
A	EP 0 768 083 A (PFIZER) 16 April 1997 (1997-04-16) cited in the application claims page 4, line 15 - line 24	1-13
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

5 April 2000

Date of mailing of the international search report

11/04/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040. Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Scarponi, U

# INTERNATIONAL SEARCH REPORT

Int'l Application No  
PCT/IB 99/01571

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 415 612 A (PFIZER) 6 March 1991 (1991-03-06) cited in the application claims page 3, line 14 - line 45 ----	1-13
A,P	WO 99 01113 A (PFIZER) 14 January 1999 (1999-01-14) claims -----	1-13



# INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/IB 99/01571

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0030081 A	10-06-1981	US 4536518 A	20-08-1985
		AT 2668 T	15-03-1986
		AU 517357 B	23-07-1981
		AU 6389780 A	07-05-1981
		BA 97149 B	28-12-1998
		BA 97150 B	28-12-1998
		BG 60333 B	27-05-1994
		CA 1130815 A	31-08-1982
		CS 9103542 A	16-12-1992
		CS 238609 B	16-12-1985
		CS 238617 B	16-12-1985
		CS 238618 B	16-12-1985
		DD 155615 A	23-06-1982
		DD 203045 A	12-10-1983
		DK 395280 A,B,	02-05-1981
		EG 15527 A	30-04-1987
		ES 496443 D	16-01-1982
		ES 8201949 A	01-04-1982
		ES 506892 D	01-09-1982
		ES 8207123 A	01-12-1982
		FI 803398 A,B,	02-05-1981
		GR 70781 A	23-03-1983
		HK 82284 A	09-11-1984
		HR 930199 B	29-02-1996
		HR 931527 B	30-04-1996
		HU 182224 B	28-12-1983
		IE 50395 B	16-04-1986
		IL 61374 A	31-10-1983
		IN 159644 A	30-05-1987
		IN 159643 A	30-05-1987
		JP 1287061 C	31-10-1985
		JP 56086137 A	13-07-1981
		JP 60005584 B	12-02-1985
		KR 8402001 B	27-10-1984
		KR 8402000 B	27-10-1984
		LU 88330 A	04-05-1994
		LV 5456 A	10-03-1994
		LV 5457 A	10-03-1994
		MX 5980 E	12-09-1984
		MY 32685 A	31-12-1985
		NO 803258 A,B,	04-05-1981
		NZ 195407 A	31-05-1984
		PH 17319 A	20-07-1984
		PT 72004 A,B	01-11-1980
		SG 56584 G	08-03-1985
		SI 8012798 A	31-12-1994
		SI 8310672 A	30-04-1996
		SU 1014467 A	23-04-1983
		SU 1034602 A	07-08-1983
		YU 67283 A	31-10-1983
CA 2143070 A	23-08-1995	NONE	
EP 768083 A	16-04-1997	AU 6053496 A	23-01-1997
		CA 2181225 A,C	18-01-1997
		CN 1147937 A	23-04-1997
		JP 9030959 A	04-02-1997

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No  
PCT/IB 99/01571

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 415612	A	06-03-1991	AT 96999 T	15-11-1993
			AU 617622 B	28-11-1991
			AU 6194390 A	18-04-1991
			CA 2024181 A,C	01-03-1991
			DE 69004529 D	16-12-1993
			DE 69004529 T	24-02-1994
			DK 415612 T	13-12-1993
			HU 58513 A	30-03-1992
			IE 63137 B	22-03-1995
			IL 95472 A	14-05-1996
			JP 3093719 A	18-04-1991
			KR 9300049 B	06-01-1993
			NZ 235100 A	26-05-1997
			PH 27544 A	18-08-1993
			PT 95118 A,B	22-05-1991
			US 5130338 A	14-07-1992
			ZA 9006882 A	29-04-1992
WO 9901113	A	14-01-1999	AU 7545098 A	25-01-1999
			EP 0980241 A	23-02-2000
			HR 980378 A	30-04-1999